Cranial Nerve Neoplasms: Clinical Trials

58 trials for Cranial Nerve Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 completed, 8 terminated, 2 active not recruiting, 2 not yet recruiting. 58 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 158Completed 41, Terminated 8, Active not recruiting 2, Not yet recruiting 2, Unknown 2, Recruiting 1, Suspended 1, Withdrawn 1
Phase 28Active not recruiting 2, Completed 2, Not yet recruiting 2, Recruiting 1, Terminated 1

Follow Cranial Nerve Neoplasms: new trials by email Literature Review of Cranial Nerve Neoplasms trials Research Report on Cranial Nerve Neoplasms

Trials (filtered) newest first · largest first

All 58 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
Trineumin - Neurofibromatosis Type II, NF2
Phase 1 / Phase 2Not yet recruitingPRG Science & Technology Co., Ltd.252026-07-012026-01-23
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma
Phase 1 / Phase 2RecruitingEli Lilly and Company272025-01-172026-11-04
Doxycycline in Cutaneous Schwannoma (NF2)
Doxycycline Injection [Doxy] - Neurofibromatosis Type 2
Phase 1 / Phase 2Active not recruitingMassachusetts Eye and Ear Infirmary192022-09-192026-10-16
Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF
Triamcinolone Acetonide 40mg/mL - Vestibular Schwannoma
Phase 1CompletedMedical University of Vienna212020-02-012022-08-24
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma
Phase 1 / Phase 2CompletedGreat Ormond Street Hospital for Children NHS Foundation Trust142019-09-262024-04-04
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide - Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma
Phase 1CompletedNational Cancer Institute (NCI)292015-07-142022-04-25
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Mebendazole, Vincristine, Carboplatin - Pilomyxoid Astrocytoma, Pilocytic Astrocytoma
Phase 1 / Phase 2Active not recruitingJulie Krystal102013-10-222026-08-06
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Photofrin (porfimer sodium) & photodynamic therapy. - Brain Tumor, Recurrent
Phase 1CompletedHarry T Whelan, MD52013-03-012019-02-25
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease
Phase 1TerminatedM.D. Anderson Cancer Center1162012-10-162026-11-05
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
Bevacizumab (Avastin) - Vestibular Schwannoma
Phase 1SuspendedNorthwell Health302011-08-012026-06-01
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
imetelstat sodium, laboratory biomarker analysis, pharmacological study - Brain and Central Nervous System Tumors, Lymphoma
Phase 1CompletedChildren's Oncology Group342011-05-012014-01-30
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
VEGF inhibitor PTC299 - Brain and Central Nervous System Tumors
Phase 1CompletedPediatric Brain Tumor Consortium282010-11-012015-05-04
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy - Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma
Phase 1CompletedNational Cancer Institute (NCI)222010-05-012015-09-29
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Phase 1TerminatedNational Cancer Institute (NCI)1292010-03-012014-11-05
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Phase 1CompletedNational Cancer Institute (NCI)272010-02-012013-05-03
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
vorinostat, bortezomib, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma
Phase 1CompletedNational Cancer Institute (NCI)202009-08-012013-07-02
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
veliparib, temozolomide, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)312009-07-012014-07-09
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
pazopanib hydrochloride, pharmacological study - Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Phase 1CompletedNational Cancer Institute (NCI)552009-06-012013-09-30
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
carboplatin, dasatinib, etoposide phosphate - Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Phase 1 / Phase 2TerminatedCity of Hope Medical Center72008-09-102026-11-04

Showing 20 of 58. Sign in to see all of them.

Narrower conditions

Optic Nerve Glioma (48)  ·  Astrocytoma (46)  ·  Medulloblastoma (43)  ·  Familial ependymoma (40)  ·  Oligodendroglioma (33)  ·  Choroid Plexus Neoplasms (32)  ·  Central Nervous System Neoplasms (30)  ·  Neuroblastoma (15)  ·  Neuroectodermal Tumors, Primitive, Peripheral (14)  ·  Rhabdoid Tumor (14)  ·  Sarcoma (12)  ·  Spinal Cord Neoplasms (12)  ·  Wilms Tumor (12)  ·  Dendritic Cell Sarcoma, Interdigitating (11)  ·  Recurrence (11)

Broader conditions

Cranial Nerve Diseases (58)  ·  Nervous System Diseases (58)  ·  Neoplasms by Histologic Type (57)  ·  Neoplasms, Nerve Tissue (57)  ·  Neuroectodermal Tumors (57)  ·  Neoplasms, Germ Cell and Embryonal (56)  ·  Neoplasms (55)  ·  Neoplasms by Site (55)  ·  Nervous System Neoplasms (54)  ·  Peripheral Nervous System Neoplasms (54)  ·  Neoplasms, Glandular and Epithelial (50)  ·  Eye Diseases (49)  ·  Optic Nerve Diseases (49)  ·  Optic Nerve Neoplasms (48)

Interventions

Filgrastim (9)  ·  Temozolomide (9)  ·  Carboplatin (8)  ·  Etoposide (4)  ·  Granulocyte Colony-Stimulating Factor (4)  ·  Bevacizumab (3)  ·  Busulfan (3)  ·  Ifosfamide (3)  ·  Irinotecan (3)  ·  O(6)-benzylguanine (3)  ·  Peripheral Blood Stem Cell Transplantation (3)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2)  ·  Cyclophosphamide (2)  ·  Melphalan (2)  ·  Radiotherapy (2)

Sponsors

National Cancer Institute (NCI) (18)  ·  Pediatric Brain Tumor Consortium (8)  ·  Children's Oncology Group (6)  ·  National Institutes of Health Clinical Center (CC) (3)  ·  City of Hope Medical Center (2)  ·  Beijing Tiantan Hospital (1)  ·  Children's Cancer and Leukaemia Group (1)  ·  Daiichi Sankyo (1)  ·  Duke University (1)  ·  Eli Lilly and Company (1)  ·  FDA Office of Orphan Products Development (1)  ·  Great Ormond Street Hospital for Children NHS Foundation Trust (1)  ·  Harry T Whelan, MD (1)  ·  Julie Krystal (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (52)  ·  Canada (7)  ·  Australia (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  China (1)  ·  Ireland (1)

Top investigators

Elizabeth Fox, MD (2)  ·  Mark W. Kieran, MD, PhD (2)  ·  Susan M. Blaney, MD (2)  ·  Aaron Tward, MD (1)  ·  AeRang Kim, MD (1)  ·  Allen R. Chen, MD, PhD, MHS (1)  ·  Amar Gajjar (1)  ·  Anna Pawlowska, MD (1)  ·  Antonio Omuro (1)  ·  Barbara Jean Bambach, MD (1)  ·  Christoph Arnoldner (1)  ·  D. Bradley Welling, MD, PhD (1)  ·  Darren Hargrave, MB Bch (1)  ·  Darren Hargrave, MD (1)  ·  Denise Adams, MD (1)

Results publications

PMID 15814645, PMID 16234526, PMID 16533779, PMID 16914576, PMID 17634493, PMID 17941066, PMID 18048828, PMID 18281544, PMID 18281546, PMID 19065567, PMID 19075272, PMID 19430790, PMID 20044751, PMID 20049936, PMID 20460632, PMID 21115653, PMID 21764821, PMID 23554030, PMID 23857966, PMID 26933802, PMID 37311055, PMID 41389341, PMID 9849694

NIH funding

U01CA081457 (9), U01CA097452 (8), P30CA008748 (1), P30CA033572 (1), U01CA069856 (1), UM1CA081457 (1)